Clinical trials: Solid Tumors (Phase 1)
Solid Tumors
A Study of ERY974 in Patient With Advanced Solid Tumors
This is the open label, multicenter Phase 1 study which consists of a dose escalation to determine the maximum tolerated dose (MTD) and cohort expansion to obtain a preliminary evaluation of anti-tumor activity.
- Trial name
- NCT02748837
- Testing
- ERY974
- Where
- 10 sites in United States, France and 1 more
- Volunteers
- 29 people
- Sponsor
- Chugai Pharmaceutical
Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
Study of NEO-201 in Solid Tumors Expansion Cohorts
The open label, first-in-human, phase 1, dose escalation component in refractory solid tumors has been completed. The Maximum Tolerated Dose and Recommended Phase 2 Dose (RP2D) was determined to be 1.5mg/kg.
- Conditions
- Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Cervical Cancer, Uterine Cancer
- Trial name
- NCT03476681
- Testing
- NEO-201 in combination with pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 121 people
- Sponsor
- Precision Biologics, Inc
Advanced Solid Tumors
Evaluation of the Safety and Efficacy of Albumin-bound Docetaxel
This trial is an open-label, single-center, dose-escalation and cohort-expansion Phase I clinical study in patients with advanced solid tumors.
- Trial name
- NCT04471675
- Testing
- Albumin-bound docetaxel
- Where
- China
- Volunteers
- 208 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Renal Cell Carcinoma, Ovarian Cancer
A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors
This is a single-center, double-arm, open-label study. this study plans to evaluate the safety and efficacy of CD70-targeting CAR-T cells in the treatment of CD70-positive advanced/metastatic solid tumors, and obtain recommended…
- Conditions
- Renal Cell Carcinoma, Ovarian Cancer, Cervix Cancer, Metastatic Cancer
- Trial name
- NCT06010875
- Testing
- CD70 CAR-T cells
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Lung Cancer, Non-Small Cell
Study of Pazopanib and Paclitaxel in Advanced Non-small Cell Lung Cancer
The Phase I part of the study will identify the doses of pazopanib and paclitaxel that can be administered safely in combination. The Phase II part of the study will not be progressed as documented in Protocol Amendment 01.
- Trial name
- NCT00866528
- Testing
- pazopanib, paclitaxel
- Where
- 4 sites in United States, United Kingdom
- Volunteers
- 30 people
- Sponsor
- GlaxoSmithKline
Patients With Advanced Solid Tumors
Safety and Tolerability of Intravenous Administration of ICVB-1042
Study to evaluate the safety and tolerability of intravenous ICVB-1042
- Trial name
- ICVB-1042 (NCT05904236)
- Testing
- Treatment with ICVB-1042 administered intravenously
- Where
- 10 sites in United States
- Volunteers
- 17 people
- Sponsor
- IconOVir Bio
Head and Neck Squamous Cell Carcinoma, Melanoma Excluding Uveal Melanoma
Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of intravenous (IV) administration of XmAb808 in combination with pembrolizumab in subjects with selected advanced solid tumors and to…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Melanoma Excluding Uveal Melanoma, Non-small Cell Lung Cancer, Squamous or Non-squamous, Urothelial Carcinoma
- Trial name
- NCT05585034
- Testing
- XmAb®808, Keytruda® (pembrolizumab)
- Where
- 12 sites in United States
- Volunteers
- 60 people
- Sponsor
- Xencor, Inc.
Advanced Solid Tumor
A Clinical Study of TQB3823 in Patients With Advanced Malignant Tumor
This is a study to evaluate the maximum tolerated dose (MTD) , occurrence of all adverse events (AEs) and serious adverse events (SAEs) , pharmacokinetic parameters and antitumor effect of TQB3823 tablets in Chinese adult…
- Trial name
- NCT05021367
- Testing
- TQB3823 tablets
- Where
- China
- Volunteers
- 164 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Solid Tumors, Lymphoma, Non-Hodgkin
Phase I Study of the Proteosome Inhibitor CEP 18770 in Patients With Solid Tumours or Non-Hodgkin's Lymphomas
This Phase 1 escalating-dose study is designed to assess, the safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel proteasome inhibitor CEP 18770, given intravenously as single agent, in patients with…
- Trial name
- NCT00572637
- Testing
- CEP-18770
- Where
- 3 sites in Italy, Switzerland
- Volunteers
- 55 people
- Sponsor
- Ethical Oncology Science
Advanced Solid Tumors
A Study of MEDI5395 in Combination With Durvalumab in Participants With Select Advanced Solid Tumors
The reason for the study is to find out if MEDI5395 and durvalumab will work and be safe for the treatment of solid tumors.
- Trial name
- NCT03889275
- Testing
- MEDI5395, Durvalumab
- Where
- 10 sites in United States, United Kingdom
- Volunteers
- 39 people
- Sponsor
- MedImmune LLC
Advanced Solid Tumors
An Open-label Phase I/II Clinical Trial of PT-112 Injection for Advanced Solid Tumors and Advanced Hepatocellular Carcinoma
Use PT-112 alone for Phase I dose escalation stage: advanced solid tumors, Phase I dose confirmation stage: advanced solid tumors. Phase II hepatocellular carcinoma (HCC).
- Trial name
- NCT03439761
- Testing
- PT-112 Injection
- Where
- China
- Volunteers
- 125 people
- Sponsor
- SciClone Pharmaceuticals
Solid Tumor Malignancies, Malignant Mesothelioma (MM)
Study of TYK-01054 Capsules in Patients With Advanced Solid Tumors
This study is to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of the TEAD inhibitor TYK-01054 capsules in patients with locally advanced or metastatic advanced solid tumors
- Trial name
- NCT07282873
- Testing
- TYK-01054
- Where
- China
- Volunteers
- 219 people
- Sponsor
- TYK Medicines, Inc
Tumors
Study Evaluating AMG 706 in Subjects With Advanced Solid Tumors
This study will determine the safety and pharmacokinetics of AMG 706 in subjects with advanced solid tumors.
- Trial name
- NCT00093873
- Testing
- Anti-angiogenesis, AMG 706
- Volunteers
- 71 people
- Sponsor
- Amgen
Advanced Solid Tumor
A Phase I Study of BR790 in Subjects With Advanced Solid Tumors
The purpose of the study was to evaluate the safety and tolerability of BR790 tablets as an oral monotherapy in subjects with advanced solid tumors, and to determine dose-limiting toxicity (DLT), maximum tolerated dose (MTD)…
- Trial name
- NCT04891653
- Testing
- BR790
- Volunteers
- 48 people
- Sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Advanced Malignant Solid Tumors
Study Evaluating Neratinib In Combination With Vinorelbine In Subjects With Advanced Or Metastatic Solid Tumors
The purposes of this study are to evaluate the safety and tolerability of neratinib in combination with vinorelbine at the maximum tolerated dose (MTD) determined in a previous study, or to determine a lower MTD of the two drugs…
- Trial name
- NCT00958724
- Testing
- Neratinib, Vinorelbine
- Where
- 2 sites in Japan
- Volunteers
- 6 people
- Sponsor
- Puma Biotechnology, Inc.
Advanced Solid Tumors, Metastatic Solid Tumors
A Dose Escalation Study Of PF-06939999 In Participants With Advanced Or Metastatic Solid Tumors
This is a Phase 1, open label, multi center, dose escalation and expansion, safety, tolerability, PK, and pharmacodynamics study of PF 06939999 in previously treated patients with advanced or metastatic cancer.
- Trial name
- NCT03854227
- Testing
- PF-06939999 dose escalation, PF-06939999 monotherapy, PF-06939999 in combination with docetaxel
- Where
- 22 sites in United States
- Volunteers
- 54 people
- Sponsor
- Pfizer
Advanced Solid Tumors
Phase I Study of HBT-708 for Patients With Advanced Solid Tumors
The purpose of this study will be to evaluate the safety, tolerability, and inital efficacy of HBT-708 in subjects with advanced solid tumors.
- Trial name
- NCT06993870
- Testing
- HBT-708
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.
Solid Tumor, Adult, Epithelial Ovarian Cancer
Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors
This is a first-in-human, Phase 1/2 open-label, multicenter, dose-escalation, safety, pharmacokinetics (PK), and biomarker study of CBX-12 in subjects with advanced or metastatic refractory solid tumors.
- Conditions
- Solid Tumor, Adult, Epithelial Ovarian Cancer, Small Cell Lung Carcinoma, Breast Cancer
- Trial name
- NCT04902872
- Testing
- CBX-12
- Where
- 4 sites in United States
- Volunteers
- 69 people
- Sponsor
- Cybrexa Therapeutics
Head and Neck Cancer, Cervical Cancer
A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors
TScan Therapeutics is developing cellular therapies across multiple solid tumors in which autologous participant-derived engeneered T cells are engineered to express a T cell receptor that recognizes cancer-associated antigens…
- Conditions
- Head and Neck Cancer, Cervical Cancer, Non-small Cell Carcinoma, Melanoma
- Trial name
- NCT05973487
- Testing
- TSC-204-A0201, TSC-204-C0702, TSC-200-A0201
- Where
- 21 sites in United States
- Volunteers
- 840 people
- Sponsor
- TScan Therapeutics, Inc.
Tumors
A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of CUDC-101 in Patients With Advanced Solid Tumors
This is a phase I, open-label, dose-escalation study of CUDC-101 in patients with advanced and refractory solid tumors. CUDC-101 is a multi-targeted agent designed to inhibit epidermal growth factor receptor (EGFR), human…
- Trial name
- NCT00728793
- Testing
- CUDC-101
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Curis, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.